Abacavir - CAS 136470-78-5
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
Abacavir
Catalog Number:
136470-78-5
Synonyms:
Ziagen
CAS Number:
136470-78-5
Description:
Abacavir sulfate is a Nucleoside analog reverse transcriptase inhibitor (NRTI); guanosine analog used to treat HIV and AIDS.
Molecular Weight:
286.33
Molecular Formula:
C14H18N6O
COA:
Inquire
MSDS:
Inquire
Targets:
HIV
Chemical Structure
CAS 136470-78-5 Abacavir

Related HIV Products


CAS 333353-44-9 NBD-556

NBD-556
(CAS: 333353-44-9)

NBD-556 is small molecule mimetic of CD4. NBD-556 recognizes the HIV-1 envelope protein gp120 and induces restructuring of gp120 analogous to CD4 binding. The C...

CAS 379270-37-8 GS-7340

GS-7340
(CAS: 379270-37-8)

Tenofovir Alafenamide is a prodrug of Tenofovir, which is a reverse transcriptase inhibitor used to treat HIV and Hepatitis B. Antiviral.

CAS 206184-49-8 Tenofovir hydrate

Tenofovir hydrate
(CAS: 206184-49-8)

Tenofovir(GS 1278, PMPA) is an antiretroviral drug known as nucleotide analogue reverse transcriptase inhibitors (NRTIs), which block reverse transcriptase, a c...

CAS 1051375-19-9 Dolutegravir sodium

Dolutegravir sodium
(CAS: 1051375-19-9)

Dolutegravir sodium salt is a HIV integrase inhibitor(IC50= 2.7 nM), modest activity against raltegravir-resistant signature mutants Y143R, Q148K, N155H, and G1...

PD 135390
(CAS: 150351-31-8)

PD 135390 has been found to be a HIV-1 protease inhibitor that could probably be effective against HIV infections.

CAS 3056-17-5 Stavudine (d4T)

Stavudine (d4T)
(CAS: 3056-17-5)

Stavudine (d4T) is a nucleoside analog reverse transcriptase inhibitor (NARTI) active against HIV.

CAS 150378-17-9 Indinavir

Indinavir
(CAS: 150378-17-9)

Indinavir is a member of the novel hydroxyaminopentane amide class of HIV-1 protease inhibitors. Indinavir is used as an antiviral.

PNU-104489
(CAS: 177577-60-5)

PNU-104489, a sulfonamidoindol derivative, has been found to be a HIV-1 specific inhibitor and was proved to exhibit activity against BHA-P-resistant HIV-1MF ha...

BMS585248
(CAS: 619331-12-3)

BMS585248 is a highly potent and novel human immunodeficiency virus type 1 (HIV-1) attachment inhibitor with 4-fluoro-6-azaindole core heterocycles. It targets ...

CAS 518048-05-0 Raltegravir

Raltegravir
(CAS: 518048-05-0)

Raltegravir (MK-0518) is a potent integrase (IN) inhibitor for WT and S217Q PFV IN with IC50 of 90 nM and 40 nM, respectively.

CAS 313682-08-5 Brecanavir

Brecanavir
(CAS: 313682-08-5)

Brecanavir is a tyrosyl-based arylsulfonamide, high-affinity, protease inhibitor (PI) for the treatment of human immunodeficiency virus type-1. This compound po...

CAS 7481-89-2 Zalcitabine

Zalcitabine
(CAS: 7481-89-2)

Zalcitabine is a nucleoside analog HIV reverse transcriptase inhibitor (NARTI).

Censavudine
(CAS: 634907-30-5)

Censavudine is a nucleoside reverse transcriptase inhibitor. It is active against HIV resistant to both abacavir and tenofovir. It is a candidate for people wit...

CAS 136470-78-5 Abacavir

Abacavir
(CAS: 136470-78-5)

Abacavir sulfate is a Nucleoside analog reverse transcriptase inhibitor (NRTI); guanosine analog used to treat HIV and AIDS.

CAS 206361-99-1 Darunavir

Darunavir
(CAS: 206361-99-1)

Darunavir is a second generation protease inhibitor that targets the HIV-1 protease. It demonstrates extremely potent activity against the infectivity and repli...

CAS 473921-12-9 Lersivirine

Lersivirine
(CAS: 473921-12-9)

Lersivirine is a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) under development for the treatment of HIV-1 infection. It prevents HIV ...

CAS 144217-65-2 YYA-021

YYA-021
(CAS: 144217-65-2)

YYA-021 enhances the neutralization sensitivity of simian-human immunodeficiency virus (SHIV) carrying the envelope from the clade B clinical human immunodefici...

Ingenol 3-Hexanoate
(CAS: 83036-61-7)

Ingenol 3-Hexanoate, an ingenol-derived compound, was more potent in reactivating latent HIV than other known activators such as SAHA, ingenol 3,20-dibenzoate, ...

CAS 149845-06-7 Saquinavir Mesylate

Saquinavir Mesylate
(CAS: 149845-06-7)

Saquinavir is an HIV Protease Inhibitor used in antiretroviral therapy. It inhibits both HIV-1 and HIV-2 proteases. Studies have also looked at saquinavir as a ...

CAS 544467-07-4 HIV-1 integrase inhibitor

HIV-1 integrase inhibitor
(CAS: 544467-07-4)

HIV-1 integrase inhibitor is uesful for anti-HIV, which can target HIV-1 integrase and depress the activity in the treatment of HIV infection, AIDS, and other s...

Reference Reading


1. Syntheses and anti-HIV activities of (±)-norcarbovir and (±)-norabacavir
Weiqiang Huang, Marvin J. Miller,* Erik De Clercqc and Jan Balzarini. Org. Biomol. Chem., 2007, 5, 1164–1166
Inspired by the fact that both aristeromycin and 5’-noraristeromycin are inhibitors of S-adenosyl-L-homocysteine hydrolase (AdoHcy hydrolase), which likely accounts for their wide spectrum of antiviral activity, we considered the syntheses of norcarbovir (1) and norabacavir (2) with the anticipation that these two desmethylene derivatives might have anti-HIV activity similar to carbovir and abacavir. Besides the possible changes in biological activity, including cytotoxicity, the removal of the 5’-methylene group would also greatly shorten synthetic routes. To date, only the syntheses of phosphate analogs of 1 have been reported, but not the parent compound 1 itself. The synthesis and biological studies of norabacavir (2) surprisingly have not been previously described. We herein report highly efficient syntheses of 1 and 2, along with their biological activities.
2. Highly efficient inhibition of human immunodeficiency virus type 1 reverse transcriptase by aptamers functionalized gold nanoparticles
Yen-Chun Shiang, Chung-Mao Ou, Huan-Tsung Chang*. Nanoscale, 2013, 5, 2756–2764
We further compare the Apt–Au NP-based inhibitors with a commercial anti-HIV drug (nucleoside RT inhibitors; abacavir) in lentivirus infectivity assays (Fig. 4). The dosage dependence of infectivity revealed that the 40Aptpol-T45–Au NPs and 40AptRH-T45–Au NPs relative to abacavir provided much higher inhibition abilities. For example, the infectivity using 40AptRH-T45–Au NPs (7.5 nM; [AptRH] ¼ 300 nM) was 40.2%, while it was 72.5% when using abacavir (10 mM). Synergistic effects of 40AptRH-T45–Au NPs/Aptpol and 40Aptpol-T45–Au NPs/AptRH were not taken into account, because of low cellular uptake of the free aptamers. 40Aptpol-T45–Au NPs/40AptRH-T45–Au NPs showed little decrease in inhibiting efficiency, mainly because of molecular crowding effect; the 40Aptpol-T45–Au NPs/40AptRH-T45–Au NPs could not easily bind to HIV-1 RT at the same time in crowdedmedia of cell plasma (Fig. 4B). As a result, the synergistic effect was weakened. Since fatal hypersensitivity reactions have been associated with therapy with abacavir, the highly effective 40AptRH-T45–Au NPs/Aptpol inhibitors hold great potential for HIV therapy.
3. Towards the development of mechanism-based biomarkers to diagnose drug hypersensitivity
N. Duran-Figueroa, J. A. Badillo-Corona, D. J. Naisbitt and J. L. Castrejon-Flores*. Toxicol. Res.,2015, 4, 777–795
As discussed above, T-cells can be activated via a processing-independent mechanism by a direct interaction between the drug, TCR and MHC membrane receptors or by the modification of self-MHC presented peptides by drugs. Neither of these binding interactions fully explains the mechanism of T-cell activation by Abacavir. Independent studies recently proposed that Abacavir binds to the F-pocket of endogenous HLA-B*57:01, altering the repertoire of self-peptides that bind and are subsequently displayed on the cell surface. Mass spectrometric analysis, X-ray crystallography and docking studies demonstrated that the drug interacts non-covalently with amino acid residues found in the F-pocket site and particularly with Ser-116 expressed exclusively in HLA-B*57:01 and no other closely related alleles (HLA-B*57:02, HLA-B*57:03, HLA-B*57:11 or HLA-B*58:01). As a result of the Abacavir–Ser-116 interaction, the peptide repertoire presented by HLA-B*57:01 is modified with peptides containing less bulky amino acids at the anchor position being preferentially presented. The presence of Abacavir during protein processing leads to a 25% shift in the peptides presented by antigen presenting cells. Analysis of HLA-B*57:01 eluted peptides showed a peak with 287.1615 mass (MH+) corresponding to Abacavir, although no trace of the metabolite bound irreversibly to peptides was detected. Importantly, only 55% of the HLA-B*57:01+ patients suffer hypersensitivity reaction to this drug suggesting that TCR clonality, metabolism or the disease itself might represent additional susceptibility factors.